The publication's current editor-in-chief is Valentin Fuster, MD, PhD. Harlan M. Krumholz, MD, will begin his five-year term in 2024.

The popular SGLT2 inhibitor, sold under the brand name Farxiga, is approved by the FDA to treat heart failure, type 2 diabetes and CKD. Recent data on its ability to affect the symptoms of heart failure patients have been inconsistent. 

Renee Bullock-Palmer, MD, director, non-invasive cardiac imaging, at the Deborah Heart and Lung Center, explains CT calcium scoring can determine if a patient needs to take aspirin and statins for prevention of coronary disease.

The policies cover a wide range of interventional therapies, including Shockwave Medical's IVL technology and intravascular ultrasound. 

CCTA has seen rapid adoption and growth over the past two years, and RSNA vendors fed that trend with new product launches.

New AFib recommendations from the American College of Cardiology and American Heart Association covered significant ground—but there is still much more to learn, experts explained. 

Cardiologists, electrophysiologists, surgeons and patient representatives all worked together on the updated guidelines, which were published in both the Journal of the American College of Cardiology and Circulation.

This is the second time in a matter of weeks the FDA has approved an RDN system for uncontrolled hypertension. The SCAI issued a statement about this trend, calling it a “game-changer for both interventional cardiology and the treatment of hypertension."